Cardiol Therapeutics Inc
TSX:CRDL

Watchlist Manager
Cardiol Therapeutics Inc Logo
Cardiol Therapeutics Inc
TSX:CRDL
Watchlist
Price: 1.87 CAD -4.59% Market Closed
Market Cap: 154.5m CAD

Cardiol Therapeutics Inc
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cardiol Therapeutics Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Cardiol Therapeutics Inc
TSX:CRDL
Free Cash Flow
-CA$25.3m
CAGR 3-Years
0%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
Canopy Growth Corp
TSX:WEED
Free Cash Flow
-CA$177m
CAGR 3-Years
33%
CAGR 5-Years
35%
CAGR 10-Years
-49%
Aurora Cannabis Inc
TSX:ACB
Free Cash Flow
-CA$28.9m
CAGR 3-Years
38%
CAGR 5-Years
48%
CAGR 10-Years
-10%
Sundial Growers Inc
NASDAQ:SNDL
Free Cash Flow
CA$49.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Free Cash Flow
-$7.6m
CAGR 3-Years
63%
CAGR 5-Years
48%
CAGR 10-Years
-9%
K
Knight Therapeutics Inc
TSX:GUD
Free Cash Flow
-CA$15.1m
CAGR 3-Years
56%
CAGR 5-Years
-7%
CAGR 10-Years
-67%

Cardiol Therapeutics Inc
Glance View

Market Cap
154.5m CAD
Industry
Pharmaceuticals

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.

CRDL Intrinsic Value
Not Available

See Also

What is Cardiol Therapeutics Inc's Free Cash Flow?
Free Cash Flow
-25.3m CAD

Based on the financial report for Mar 31, 2025, Cardiol Therapeutics Inc's Free Cash Flow amounts to -25.3m CAD.

What is Cardiol Therapeutics Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-20%

Over the last year, the Free Cash Flow growth was -14%.

Back to Top